Liver health may change how cancer drug works
NCT ID NCT04953910
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) is processed by the body in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to find safe dosing for those with liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BIO1
WITHDRAWNVilnius, Lithuania
-
Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p.
RECRUITINGWroclaw, 51-162, Poland
-
Complex Oncology Center - Plovdiv - Base II
WITHDRAWNPlovdiv, Bulgaria
-
Erebuni Medical Center
RECRUITINGYerevan, Armenia
-
Hematology Center After Prof. R. Yeolyan (Adult Blood Disorders)
RECRUITINGYerevan, Armenia
-
Hematology Center After Prof. R. Yeolyan (Clinic of Adults Oncology)
RECRUITINGYerevan, Armenia
-
Hospital Clínico Universitario Virgen de la Arrixaca (Hematology Dept)
RECRUITINGMurcia, 30120, Spain
-
Hospital Clínico Universitario Virgen de la Arrixaca (Solid Tumor Dept)
RECRUITINGMurcia, Spain
-
Hospital Universitari Arnau de Vilanova
RECRUITINGLleida, Spain
-
Hospital Universitari Dexeus - Grupo Quirónsalud
WITHDRAWNBarcelona, Spain
-
Hospital Universitari i Politècnic La Fe
TERMINATEDValencia, Spain
-
Hospital Universitario 12 de Octubre
WITHDRAWNMadrid, Spain
-
Hospital Universitario La Paz
RECRUITINGMadrid, 28046, Spain
-
Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu
RECRUITINGBucharest, 22328, Romania
-
Institutul Oncologic Prof. Dr. Ion Chiricuta
RECRUITINGCluj-Napoca, 400015, Romania
-
MD Anderson
RECRUITINGHouston, Texas, 77030, United States
-
National Center of Oncology Named After V.A. Fanarjyan
RECRUITINGYerevan, Armenia
-
START Barcelona - Hospital HM Nou Delfos
RECRUITINGBarcelona, 8023, Spain
-
START Madrid - CIOCC - HM Sanchinarro
RECRUITINGMadrid, 28050, Spain
-
START Madrid - Hospital Universitario Fundación Jiménez Díaz
RECRUITINGMadrid, 28040, Spain
-
START Rioja - Hospital de San Pedro
NOT_YET_RECRUITINGLa Rioja, 26006, Spain
-
Summit Clinical Research s.r.o
RECRUITINGBratislava, 831 01, Slovakia
Contact
Conditions
Explore the condition pages connected to this study.